FX 322

Drug Profile

FX 322

Alternative Names: FX-322

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Frequency Therapeutics
  • Class Small molecules
  • Mechanism of Action Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Sensorineural hearing loss

Most Recent Events

  • 15 Feb 2018 Frequency Therapeutics plans to launch phase II studies for Sensorineural hearing loss in USA in 2018
  • 21 Dec 2017 Frequency Therapeutics completes a phase I trial in Sensorineural hearing loss in Australia (NCT03300687)
  • 30 May 2017 Phase-I clinical trials in Sensorineural hearing loss in Australia (Intratympanic) (ACTRN12617000704392) (NCT03300687)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top